By Bachem AG
To get in touch with Bachem AG, simply fill out the form below.
Subscribe to Supplier
Bachem Nominated for Swiss Biotech Success Story Award 2021
Bubendorf, Switzerland: – The Swiss Biotech Association has nominated peptide technology specialist Bachem AG for its 2021 Swiss Biotech Award.
The association’s annual Swiss Biotech Success Stories showcase valuable accomplishments by the biotech industry in Switzerland and honor individual people who have made important and sustainable contributions to the industry.
Vision and Innovation
The 2021 award nomination recognizes Bachem’s success story as a highly innovative company and founder Dr. Peter Grogg for his vision, his flair for entrepreneurial thinking and courage in taking risks.
Bachem has been shortlisted for a number of accomplishments, including achieving lasting impact, creating jobs in Switzerland and becoming an enabler for the biotech industry.
Partner of choice
Through innovative ideas, sustainable actions and conscientious work, Bachem’s people contribute every day to maintaining Bachem’s lead over competitors in the marketplace as the partner of choice for the biotech and pharmaceutical industry.
The company commented: “Together as a team, we plan to carry this success story onward into the future. We look forward to learning whether we will be the ones to receive the prize in April 2021.”
The Swiss based Bachem Group is a public, innovation-driven company specializing in the development and manufacturing of pepTides, oligonucleoTides and complex organic molecules as active pharmaceutical ingredients (APIs). A comprehensive catalog of innovative biochemicals for research and exclusive custom syntheses for research labs complete its service portfolio.
With 50 years of experience, headquartered in Switzerland with subsidiaries in Europe, the US and Asia, the group has a global reach and shows total commitment to quality, innovation and partnership to its customers worldwide.
Under its banner Leading Partner in Tides, Bachem prioritizes continuous investment in R&D on chemistries and technologies as crucial for future success. Its ever-increasing knowledge of complex proteins and peptides derives from ongoing research in proteomics, as well as progress in mass spectrometry, synthesis and ligation technologies, complemented by collaboration with external research institutions.
Bachem has five production sites in the US, UK and Switzerland along with research level production and full cGMP manufacturing facilities on both continents. These provide capacity to produce APIs, key intermediates, small molecule generics, and new chemical entities (NCEs) at preclinical, clinical and production scales.
Further information at: www.bachem.com
About Swiss Biotech Association
Founded in 1998, the Swiss Biotech Association represents the interests of the Swiss biotechnology industry, collaborating with numerous partners and life science clusters globally under the brand Swiss Biotech™.
To support its members in a competitive market, the Zurich-based Association works to secure favorable framework conditions and facilitate access to talents, novel technologies and financial resources.
Its core mission is to ensure that the value generated by the Swiss biotech industry continues to grow and that the industry contributes to the well-being of the socio-economic ecosystem thereby enabling Switzerland to be a key player at the forefront of bioscience innovation.
Further information at: http://www.swissbiotech.org/